M. Dreyling
Ludwig Maximilian University of Munich
18 Papers
128 Citations
M. Dreyling is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Mantle cell lymphoma & Medicine. The author has an hindex of 4, co-authored 11 publications. Previous affiliations of M. Dreyling include University of Washington.
Chat about Author
Papers
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.
Stephen E. Spurgeon,Brian G. Till,Peter Martin,Andre Goy,M. Dreyling,Ajay K. Gopal,Michael LeBlanc,John P. Leonard,Jonathan W. Friedberg,Lawrence Baizer,Richard F. Little,Brad S. Kahl,Mitchell R. Smith +12 more
TL;DR: Clinical trials are needed that prospectively stratify patients on the basis of MCL biology and disease risk, incorporate novel agents, and use MRD to guide the need for additional therapy.
14
Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
Simone Ferrero,Alessandro Pastore,Christian Scholz,Roswitha Forstpointner,Antonio Pezzutto,Lothar Bergmann,Lorenz Trümper,Jürgen Finke,Ulrich Keller,Paola Ghione,Roberto Passera,Wolfgang Hiddemann,Oliver Weigert,M. Unterhalt,M. Dreyling +14 more
TL;DR: Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
14
S206: obinutuzumab plus chemotherapy demonstrates long-term benefit over rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: final analysis of the gallium study
William Townsend,Wolfgang Hiddemann,Christian Buske,Guillaume Cartron,Dennis D. Cunningham,Martin J. S. Dyer,John G. Gribben,E. Phillips,M. Dreyling,John F. Seymour,Andrew Grigg,Ting-Yu Lin,Xiaonan Hong,D. Kingbiel,Tina Nielsen,Andrea Knapp,Michael Herold,Robert Marcus +17 more
TL;DR: Townsend et al. as mentioned in this paper reported the final analysis of the GALLIUM study after a median observation time of 8 years, where the primary endpoint was investigator-assessed PFS; secondary endpoints included time-to-next anti-lymphoma treatment (TTNLT), overall survival (OS) and incidence of adverse events (AEs).
10